Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622869 | 0.85 | L3MBTL1 (0.56) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL948318 | 0.85 | MAPT (0.59) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL4688032 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL7837046 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HPGDNPC1RAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL22346017 | 0.83 | MAPT (0.58) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL7995454 | 0.82 | PDCD1 (0.50) | ALDH1A1HPGDPOLBHDAC3HDAC4 | |
| SCHEMBL19900562 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL30168125 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDNPC1RAB9APOLB | |
| SCHEMBL3530917 | 0.82 | L3MBTL1 (0.49) | ALDH1A1HPGDL3MBTL1POLBHDAC3 | |
| SCHEMBL6691064 | 0.82 | ALDH1A1 (0.50) | ALDH1A1HPGDL3MBTL1POLBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3503730-B1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230101227-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-03-30 | — | — | US | disclosed |
| US-11390642-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| EP-3503730-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018039364-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| CN-101501005-A | Arylaminoaryl-alkyl-substituted imidazolidine-2, 4-diones, processes for their preparation, medicaments comprising these compounds and their use | SANOFI AVENTIS (FR) | 2009-08-05 | — | — | CN | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| CN-101312957-A | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) | NOVARTIS AG (CH) | 2008-11-26 | — | — | CN | disclosed |
| WO-2008118784-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | TARGANTA THERAPEUTICS CORP. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008053479-A1 | SELF-IMMOLATIVE POLYMERS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-05-08 | — | — | WO | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-6348616-B1 | CHEMICAL INTERMEDIATES FOR SYNTHESIS OF DESIRED BENZOXAZINONES | PIERCE MICHAEL ERNEST (US) | 2002-02-19 | — | — | US | disclosed |
| US-6147210-A | Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1998004535-A1 | A PRACTICAL SYNTHESIS OF BENZOXAZINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | ALDH1A1 2398/4885HPGD 2578/4885NPC1 3005/4885 |
| US-20230101227-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | GSS, GSR, RNMT | ALDH1A1 1098/4885HPGD 560/4885NPC1 2539/4885 |
| US-11390642-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, GSTA2 | ALDH1A1 864/4885HPGD 1118/4885NPC1 3745/4885 |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | GSS, GSR, RNMT | ALDH1A1 1098/4885HPGD 560/4885NPC1 2539/4885 |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | ALDH1A1 1249/4885HPGD 1044/4885NPC1 2269/4885 |
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | ALDH1A1 2132/4885HPGD 3896/4885NPC1 1038/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | ALDH1A1 1249/4885HPGD 1044/4885NPC1 2269/4885 |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, RNMT | ALDH1A1 1098/4885HPGD 560/4885NPC1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.